Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...
The stock's rise snapped a four-day losing streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback